Access to therapy in the multicenter AIDS Cohort Study, 1989-1992

Keyphrases

• Outpatient Visits 100%
• Pneumocystis Jirovecii 100%
• Multicenter AIDS Cohort Study 100%
• Access to Therapy 100%
• Insurance 66%
• Antiretroviral Therapy 66%
• Human Immunodeficiency Virus Type 1 (HIV-1) 66%
• College Education 66%
• Insurance Status 66%
• Health Service Utilization 66%
• Antiretroviral 33%
• Zidovudine 33%
• Hospitalization 33%
• Drug Use 33%
• Aerosolized 33%
• Multivariate Model 33%
• Immunosuppression 33%
• Trimethoprim-sulfamethoxazole (TMP-SMX) 33%
• Dapsone 33%
• Pentamidine 33%
• Previous Hospitalization 33%
• Zalcitabine 33%
• Dideoxycytidine 33%
• Didanosine 33%
• HIV-related 33%
• Combined Antiretroviral Therapy (cART) 33%
• Ketoconazole 33%
• Fluconazole 33%
• Income Status 33%
• Secular Trends 33%
• White Race 33%
• Antifungal Prophylaxis 33%
• Robust Variance 33%
• Variance Estimate 33%
• Clinical Status 33%
• CD4 Lymphocyte Count 33%
• Acyclovir 33%
• Person Correlation 33%
• Utilization Status 33%
• Multiple Logistic Regression 33%

Nursing and Health Professions

• Acquired Immune Deficiency Syndrome 100%
• Cohort Analysis 100%
• Human Immunodeficiency Virus 42%
• Outpatient 42%
• Pneumocystis Pneumonia 42%
• Antiretroviral Therapy 42%
• Education 42%
• Prevalence 28%
• Zalcitabine 28%
• Health Care 28%
• Multivariate Logistic Regression Analysis 14%
• CD4 Lymphocyte Count 14%
• Zidovudine 14%
• Drug Use 14%
• Health Status 14%
• Cotrimoxazole 14%
• Pentamidine 14%
• Dapsone 14%
• Immunosuppressive Treatment 14%
• Didanosine 14%
• Fluconazole 14%
• Aciclovir 14%
• Ketoconazole 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Acquired Immune Deficiency Syndrome 100%
• Cohort Study 100%
• HIV 42%
• Pneumocystis Pneumonia 42%
• Prevalence 28%
• Zalcitabine 28%
• Health Status 14%
• Cotrimoxazole 14%
• Pentamidine 14%
• Dapsone 14%
• Didanosine 14%
• Aciclovir 14%
• Ketoconazole 14%
• Fluconazole 14%
• Zidovudine 14%
• Antiviral Drug 14%